Twitter suspends over 70 million accounts in 2 months: Washington Post

Washington, Jun 24: Twitter has once again flagged a tweet from US President Donald Trump which promoted violence by saying if protesters tried to set up an "autonomous zone" in Washington, DC they would be met with "serious force".

This is the fourth time Twitter has red flagged Trump's tweet for glorifying violence or violating its policies.

Trump has been critical of the "autonomous zone" in Seattle, an area occupied by protestors for much of this month.

"We've placed a public interest notice on this Tweet for violating our policy against abusive behaviour, specifically, the presence of a threat of harm against an identifiable group," Twitter's safety team tweeted late Tuesday.

Trump had tweeted: "There will never be an ‘Autonomous Zone' in Washington, D.C., as long as I'm your President. If they try they will be met with serious force!"

Twitter earlier labeled a video tweeted by him which mocked CNN as manipulated media.

According to Twitter, "this Tweet has been labeled per our synthetic and manipulated media policy to give people more context".

In May, Twitter labeled two Trump tweets that made false claims about mail-in ballots in California.

Twitter later labeled another Trump tweet glorifying violence in which he said, "when the looting starts, the shooting starts."

Facebook also removed a Trump campaign ad featuring a symbol used by Nazis for political dissenters, saying the ad violated its policies.

London, Apr 22: The UK government on Tuesday announced a 20 million pounds funding for a University of Oxford project working on developing a vaccine against the novel coronavirus, which is now ready for acceleration as it begins human trials from Thursday.

UK Health Secretary Matt Hancock told the daily Downing Street briefing that the Department for Health was “throwing everything” at trying to find a vaccine because it is a critical aspect of the COVID-19 pandemic fight and lifting the strict lockdown measures in place to curb its spread.

Another 22.5 million pounds is being made available to Imperial College London to support its phase-two clinical trials for them to begin the work on a very large phase three trial.

"Normally it would take years to get to this point," said Hancock.

"The UK is at the forefront of the global effort – we've put in more money than any other into the global search for a vaccine. Nothing about this is inevitable. Vaccine production is a matter of trial and error. But the UK will throw everything it has at trying to find one,” he said.

The announcement came as Britain had another major daily leap in the hospital death toll from coronavirus, up by 823 to hit 17,337 on Tuesday.

But the Cabinet minister said the government's plan to control the rapid spread of the virus and prevent the state-funded National Health Service (NHS) from being overwhelmed is working as the number of hospitalisations with COVID-19 was showing a downward trajectory.

In reference to a major issue in the last few weeks of a critical shortage of personal protective equipment (PPE) for doctors and nurses on the frontlines of COVID-19 treatment, the minister said the supply problems are being addressed by actively engaging with thousands of companies, including 159 UK manufacturers.

“We are determined to get people the PPE they need. This is a 24/7 operation, one of the biggest cross-government operation I have ever seen," said Hancock.

Washington, Mar 28: A US-based lab has unveiled a portable test that can tell if someone has COVID-19 in as little as five minutes, it said in a statement Friday.

Abbot Laboratories said the US Food and Drug Administration (FDA) had given it emergency authorization to begin making the test available to healthcare providers as early as next week.

The test, which is the size of a small toaster and uses molecular technology, also shows negative results within 13 minutes, the company said in a press statement.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Abbot president and chief operating officer Robert Ford.

The test's small size means it can be deployed outside the "traditional four walls of a hospital in outbreak hotspots," Ford said, and Abbott is working with the FDA to send it to virus epicenters.

The test has not been cleared or approved by the FDA, and has only been authorized for emergency use by approved labs and healthcare providers, the company said.